Skip to main content
OpenTrials
Completed

NCT Number: NCT05508607

Precision Antimicrobial STewardship for Clostridioides DIfficile Prevention

To decrease CDI incidence by implementing an electronic health record-integrated CDI-risk classification tool for Clostridioides difficile infection (CDI) to focus a bundle of antimicrobial stewardship (AMS) CDI prevention recommendations on high-risk patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

CDI

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Intermountain Medical Center

Salt Lake City, Utah, 84107, United States

About this study

This study aims to use a pre/post implementation design to evaluate the use of a novel risk classification tool to improve existing methods of identifying patients eligible for routine antimicrobial stewardship (AMS) care processes targeting reduction of Clostridioides difficile infection (CDI). Antimicrobial stewardship is an established, evidence-based quality improvement program that is required by The Joint Commission and a condition of participation by the Centers for Medicare and Medicaid. AMS processes of care are evidence based, supported by published research demonstrating outcomes benefits, are recommended by national guidelines and are not investigational. Treatment decisions remain at the discretion of clinicians and patients

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • adult acute care patients identified as high-CDI risk by the CDI risk classification tool. This sub-group represents approximately 6% of all acute care admissions

Exclusion criteria

  • Behavioral health units
  • Inpatient rehabilitation units
  • Labor and Delivery units
  • Same day surgery and observation units

Treatment and study plan

CDI-risk Classification Tool

Other

This tool will focus a bundle of antimicrobial stewardship (AMS) CDI prevention recommendations on high-risk patients.

Primary outcomes

  1. Per-Admission Rate

    Time frame: 30 days after discharge

    per-admission rate of hospital-associated CDI, defined as: positive toxin B by enzyme-linked immunoassay or polymerase chain reaction test at least 72 hours after admission

Secondary outcomes

  1. Total Antibiotic Usage

    Time frame: through study completion, an average of 1 year

  2. High-Risk Antibiotic Usage

    Time frame: through study completion, an average of 1 year

  3. Proton Pump Inhibitor Therapy Administered

    Time frame: through study completion, an average of 1 year

  4. Total Variable Cost per Admission

    Time frame: through study completion, an average of 1 year

  5. Hospital Length of Stay

    Time frame: through study completion, an average of 1 year

Sponsors and collaborators

Lead sponsor

Intermountain Health Care, Inc.

Other

Registry information

Acronym: PASTCDI

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Aug 19, 2022
Registry last updated
Aug 19, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.